Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
about
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitusSaxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin.Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Metformin + saxagliptin for type 2 diabetes.Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.Fixed-dose combinations for treatment of type 2 diabetes mellitus.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.New fixed dose chemical combinations: the way forward for better diabetes type II management?Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.Scaffold-based design of xanthine as highly potent inhibitors of DPP-IV for improving glucose homeostasis in DIO mice.
P2860
Q34407893-6F50AD1F-3997-441C-92F1-8DA195B233BEQ35411329-6CCCA42A-BDB9-4F72-AB6B-1119718BD5F8Q36169413-B739C326-D17B-4C3E-A3BC-956B9792D7F1Q37331171-E23491F7-9646-4073-84B3-D99EB59B7C3BQ37446672-E057BA93-E39D-4A82-A519-4FFA696F103EQ37948831-D789D156-34CB-4599-94C5-9E576C987AA8Q37965618-F964FCAA-77AF-4858-BB69-F494E765AFF6Q37973413-93ADF11D-DCEE-40D4-85C8-716EF590EAD2Q37978206-F9EA9A1E-CDBB-4125-8333-F09CAFE2FB56Q37982112-978C1D92-003A-4DFB-87FD-6CBFF2B9A6D6Q38113092-34A4F3E5-EA1F-4C84-8A50-923D92DDC96AQ38971792-A5A63EEC-41D3-43FB-BD4A-A59DA39B388CQ45402744-C4A33E81-C8FE-4E71-A810-8F24038CA689Q51009291-032C09FA-8D54-4270-A6B7-6D16093D8412
P2860
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@en
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@nl
type
label
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@en
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@nl
prefLabel
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@en
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@nl
P2860
P356
P1476
Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.
@en
P2093
Pamela Kushner
Priscilla A Hollander
P2860
P356
10.3810/PGM.2010.05.2144
P407
P577
2010-05-01T00:00:00Z